Authors: Witt, Kristina; Evans-Axelsson, Susan; Lundqvist, Andreas; Johansson, Martin; Bjartell, Anders; Hellsten, Rebecka
Online: https://doi.org/10.1007/s00262-021-02915-6
Issue: Cancer Immunol Immunother . 2021 Mar 31.
Abstract
There is an urgent need for new treatment options in metastatic drug-resistant prostate cancer. Combining immunotherapy with other targeted therapies may be an effective strategy for advanced prostate cancer. In the present study, we sought to investigate to enhance the efficacy of anti-CTLA-4 therapy against prostate cancer by the combination with STAT3 inhibition.
